Decision Diagnostics Corp (OTCMKTS: DECN) continues to be among the most talked about and active stocks in small caps in recent weeks. DECN has been one of the top most traded stocks on the entire OTC for a while now boasting a massive following and legions of shareholders. The stock traded as low as $0.05 after the suspension but has now come back to the level it traded at beforehand and easily tops several million USD$ in daily dollar volume.
In a recent open letter DECN CEO Keith Berman stated “As a leading provider of diabetic testing kits for two decades and an early applicant for FDA EUA authorization of its testing kits to detect the Covid-19 virus, DECN has been continuing its testing efforts overseas while actively seeking FDA approval for testing protocols in the U.S. DECN’s Pharma Tech Solutions subsidiary first submitted its proposed GenViro! professional use device to the FDA on April 3, 2020, almost three months ago in the middle of a pandemic.
Decision Diagnostics Corp (OTCMKTS: DECN) is an 18-year old, diabetes and now disease testing bio-technology development firm. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company’s GenUltimate TBG product is not yet available for sale in the United States or Puerto Rico but is for sale in select International markets since late February 2020.
The big story on DECN is its GenViro(TM) Corona Virus Screening Kit which “provides results in 15 seconds, based on a small finger prick blood sample.” The company’s methodology employs a simple, easy to use, swift (15 seconds and faster than Rapid) method for determining the presence of a virus in blood lyced into blood plasma. Blood sample requirements are 1-2 microliters. DECN designed and tested the kit in Daegu, South Korea already and therefore are confident of the success of their kit application testing for the FDA.
To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
CEO Keith Berman stated last week “While the FDA has issued more than 100 EUA approvals for tests and products related to Covid-19, some of the most promising have been left on the sidelines. To be sure, we need our public health policy officials to be thorough and keep us all safe. At the same time, we need them to resist the urge to go through the motions. That means pushing the envelope, avoid taking the easier way out and stop being co-opted by, ‘the big guys.’ Lives and our economy are at stake. All experts agree it is critical to identify those who are currently infected, many of whom are presumably asymptomatic, to protect those who are not and we need to act now with safety and urgency to be successful in this battle.”
He concluded: As the world searches for testing solutions, and we need them now, some companies such as ours who have their testing foundations in long accepted technologies that are being re-thought and re-engineered for purposes beyond their original intentions, remain seated on the bench, at least in the U.S. In overseas testing, our test kit identifies the virus in seconds, while in the U.S. we are asked to jump through regulatory “hoops” seemingly made up just for us. To be sure, we need our public health policy officials to be thorough and keep us all safe. At the same time, we need them to resist the urge to go through the motions. That means pushing the envelope, avoid taking the easier way out and stop being co-opted by, “the big guys.” And to stop applying pre-conceived notions of science that apply to conventional technologies and force fit their use to new technological approaches. Lives and our economy are at stake. While not the time to overhaul the system, the system must show it can be flexible and act with safety, urgency and open-mindedness to the less-familiar that could hold the key to saving lives and getting our economy, and perhaps world economies, back on track.
Microcapdaily has been covering DECN since the stock was $0.03. We stated on March 3 when DECN first started moving “Decision Diagnostics Corp (OTCMKTS: DECN) is on a fast rise after the Company announced its new screening methodology for the Coronavirus (Covid19). According to DECN the product is timely, simple to use, cost effective and will be commercial ready in the summer of 2020.
We have a Monster Pick Coming. Subscribe Right Now!
Currenly trading at a $72 million market valuation DECN has recently come back into the trading range it was at before the suspension. The stock still carries the dreaded skull and crossbones designation from otcmarkets. According to DECN its GenViro(TM) Corona Virus Screening Kit easily tops anything on the market; GenViro! provides results in 15 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19. Microcapdaily has been covering DECN since the stock was .o3. We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.